Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2018 · 10-Q
Revenue$8.17K$8.17K+118.7% vs Q2 2017 Net Income-$1.68M-$1.68MN/M vs Q2 2017 EPS Diluted-$0.03-$0.03N/M vs Q2 2017 Gross Profit$5,893+161.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,587,771N/M Margins · derivedGross margin72.1%+11.8 pt vs Q2 2017
Operating margin-16405.7%−4708.3 pt vs Q2 2017
Net margin-20535.4%−5427.4 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 14, 2018 · 45 d after period end